

Cancer Society of New Zealand Auckland Northland Division Incorporated

Separate and Consolidated

General Purpose Financial Report for the year ended 31 March 2025

Contents	Pages
Directory	1
Independent auditor's report	2
Separate and Consolidated Statement of Service Performance	5
Separate and Consolidated Financial Statements	
Statements of comprehensive revenue and expense	8
Statements of changes in net assets/equity	9
Statements of financial position	10
Statements of cash flows	11
Notes to and forming part of separate and consolidated financial statements	12-22

Cancer Society of New Zealand Auckland Northland Division Incorporated

Directory for the year ended 31 March 2025

DATE OF INCORPORATION 20 February 1951

REGISTERED OFFICE 1 Boyle Crescent
Grafton
Auckland

CHARITIES REGISTRATION NUMBER CC22556

INCORPORATION NUMBER 221619

PRESIDENT C Kinser

INDEPENDENT AUDITOR BDO Auckland
Auckland

BANKERS ANZ Bank
Auckland

SOLICITORS Armstrong Murray Lawyers
Auckland

Copeland Ashcroft Law Limited
Auckland

**INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF CANCER SOCIETY OF NEW ZEALAND AUCKLAND NORTHLAND DIVISION
INCORPORATED**

Opinions

We have audited the separate and consolidated general purpose financial report of Cancer Society of New Zealand Auckland Northland Division Incorporated ("the Society") and its controlled entity (together, "the Group"), which comprises the separate and consolidated financial statements on pages 8 to 22 and the separate and consolidated statements of service performance on pages 5 to 7. The complete set of separate and consolidated financial statements comprise the separate and consolidated statements of financial position as at date, and the separate and consolidated statements of comprehensive revenue and expense, separate and consolidated statements of changes in net assets/equity and separate and consolidated cash flow statements for the year then ended, and notes to the separate and consolidated financial statements, including a summary of significant accounting policies.

Opinion on the Separate and Consolidated Statements of Service Performance

In our opinion, the accompanying separate and consolidated general purpose financial report presents fairly, in all material respects, the separate and consolidated statements of service performance for the year ended 31 March 2025, in that the service performance information is appropriate and meaningful and prepared in accordance with the Society's and Group's measurement bases or evaluation methods, in accordance with Public Benefit Entity Standards Reduced Disclosure Regime ("PBE Standards RDR") issued by the New Zealand Accounting Standards Board.

Qualified Opinion on the Separate and Consolidated Financial Statements

In our opinion, except for the effects of the matter described in the *Basis for Qualified Opinion on the Separate and Consolidated General Purpose Financial Report* section of our report, the accompanying separate and consolidated general purpose financial report presents fairly, in all material respects, the separate and consolidated financial position of the Society and Group as at 31 March 2025, and its separate and consolidated financial performance and its cash flows for the year then ended in accordance with PBE Standards RDR.

Basis for Qualified Opinion on the Separate and Consolidated Financial Statements

Included in the separate and consolidated statements of comprehensive revenue and expense for the year ended 31 March 2025 is revenue from donations, appeals, grants & events and memoriam received in cash, amounting to \$820,452. Control over such revenues prior to being recorded is limited. Consequently, there were no practical audit procedures we could perform to confirm independently that all cash revenue items were properly recorded. Accordingly, we were unable to determine the completeness of revenue and the related cash flows.

We conducted our audit of the consolidated financial statements in accordance with International Standards on Auditing (New Zealand) ("ISAs (NZ)") and the audit of the separate and consolidated service performance information in accordance with the ISAs (NZ) and New Zealand Auditing Standard 1 (NZ AS 1) (Revised) *The Audit of Service Performance Information (NZ)*. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Separate and Consolidated General Purpose Financial Report* section of our report. We are independent of the Society and Group in accordance with Professional and Ethical Standard 1 *International Code of Ethics for Assurance Practitioners (including International Independence*

Standards) (New Zealand) issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Other than in our capacity as auditor we have no relationship with, or interests in, the Society or its controlled entity.

The Boards' Responsibilities for the Separate and Consolidated General Purpose Financial Report

The Board is responsible on behalf of the Society and Group for:

- (a) the preparation and fair presentation of the separate and consolidated financial statements and separate and consolidated statements of service performance in accordance with PBE Standards RDR;
- (b) the selection of elements/aspects of service performance, performance measures and/or descriptions and measurement bases or evaluation methods that present separate and consolidated statements of service performance that is appropriate and meaningful in accordance with PBE Standards RDR;
- (c) the preparation and fair presentation of the separate and consolidated statements of service performance in accordance with the Society's and Group's measurement bases or evaluation methods, in accordance with PBE Standards RDR;
- (d) the overall presentation, structure and content of the separate and consolidated statements of service performance in accordance with PBE Standards RDR; and
- (e) such internal control as the Board determine is necessary to enable the preparation of the separate and consolidated financial statements and separate and consolidated statements of service performance that are free from material misstatement, whether due to fraud or error.

In preparing the separate and consolidated general purpose financial report, the Board is responsible on behalf of the Society and Group for assessing the Society's and Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board either intends to liquidate the Society or Group or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Separate and Consolidated General Purpose Financial Report

Our objectives are to obtain reasonable assurance about whether the separate and consolidated financial statements as a whole, and the separate and consolidated statements of service performance are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (NZ) and NZ AS 1 (Revised) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decisions of users taken on the basis of this separate and consolidated general purpose financial report.

A further description of our responsibilities for the audit of the separate and consolidated general purpose financial report is located at the External Reporting Board's website at:
<https://www.xrb.govt.nz/standards/assurance-standards/auditors-responsibilities/audit-report-13-1/>

This description forms part of our auditor's report.

Who we Report to

This report is made solely to the Society's members, as a body. Our audit work has been undertaken so that we might state those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Society and the Society's members, as a body, for our audit work, for this report or for the opinions we have formed.

BDO Auckland

BDO Auckland
Auckland
New Zealand
13 August 2025

Cancer Society of New Zealand Auckland Northland Division Incorporated

Separate and Consolidated

Statements of Service Performance

for the year ended 31 March 2025

Cancer Society of New Zealand Auckland Northland Division Incorporated (CSAN)

The role of CSAN is:

To improve community well-being by reducing the impact and incidence of cancer in all communities in Auckland and Northland

Its goals are to:

- be a respected voice on cancer prevention, care and survivorship
- be a valued partner within the health sector locally, nationally and internationally
- use resources efficiently to deliver equitable cancer outcomes for people, whānau and populations
- ensure CSAN is anchored in our communities in the high-value services we deliver

In order to meet the mission and goals of CSAN, the organisation operates in a number of functional areas. These include;

Support Services

Support Services continued to increase in activity in response to continued need. The support provided varies according to need and making the best use of our limited resources. A feature of the past year was the growth in contacts other than face to face.

It employed 40 staff as at 31 March 2025 (2024: 34). They include Nurses, Counsellors, Social workers, Psychologists and support staff and are primarily located at the Auckland and Whangarei offices. Clinics are also carried out in South and West Auckland. Nurses and support staff also conduct home visits.

Our equity initiative- Kia ora e Te Iwi was reviewed during the year. This resulted in the amalgamation of the staff with the Cancer Prevention team, resulting in a combined approach across both areas. In addition, iwi health providers are engaged to assist support services in the Te Tai Tokerau area.

Service	Description	2025	2024
Referrals	Individuals with at least one contact with Cancer Society Support Services	3,674	3,744
Contacts in person	Interaction face to face including home visits (excl Psychology)	7,043	6,530
Contacts - Other	Includes mail, email, text, video, phone (excl Psychology)	58,961	53,421
Psychology	Psychosocial support sessions provided to patients and whanau	1,742	2,080
Driving Services	Drives provided to patients (including volunteers)	3,855	3,905

Research

CSAN funds a range of cancer research projects and programmes directly and supporting the national Cancer Society programme.

Year	2025	2024
Research Expenditure	\$2,644,507	\$2,557,585

Domain Lodge

Domain Lodge provides 52 rooms for patient use and a further seven flats alongside the main building (2024: 52 rooms and a further 4 flats). The majority of these patients stay free of charge due to the provision of Te Whatu Ora's National Travel Assistance funding, and the support of CSAN.

Domain Lodge was opened in 1999. A much-needed interior refurbishment commenced in January 2025, leading to reduced room availability at times, and consequently less guests were able to be accommodated while work was carried out.

Year	2025	2024
Patient bed nights at Domain Lodge	29,522	31,050

Volunteer Services

Our Volunteer team arranges support in a number of areas of CSAN, particularly events. This is most noticeable for the Daffodil Day event, our major volunteer activity where volunteers are an important presence across the Auckland Northland region.

Other activities that utilise the services of Volunteers include the Driving Service, Hospital Oncology Wards, and at Domain Lodge.

Fundraising and Community Events

CSAN fundraising events are an important part of CSAN fundraising and community involvement.

Our significant events are as follows.

Significant Events	2025	2024
Daffodil Day	Held	Held
Relay for Life – various locations	Held	Held
Longest Day	Held	Held
Auckland Marathon (Charity Partner)	Held	Held
Games Fair	Held	Held
Jump for Cancer	Held	Held

Contribution to the Health Sector

The Cancer Society of New Zealand comprises a National Office in Wellington and five regional divisions including CSAN. Much of the advocacy work and submissions on health matters are presented by National Office. CSAN provides support and the consumer 'voice' from our regional Cancer Prevention team.

The Davis Carr Cancer Society Endowment

The Davis Carr Cancer Society Endowment Trust ("the Trust") was established in 2008 with a gift from CSAN and donations from Ted and Mollie Carr and the estate of Sir Ernest Davis.

The primary purposes of the Trust are;

- i. To maintain and develop the Domain Lodge and any other similar residential facilities operated by the Cancer Society in the Auckland region from time to time for the purpose of assisting cancer patients.
- ii. As an ancillary purpose to assist with the day to day work and activities of the Cancer Society to the extent that these activities are charitable from time to time.

To meet the purposes of the Trust, investment funds are held by the Trust, and the net income from the fund, and other funds received by way of donations and grants from time to time increase its value.

Funds are solely distributed to CSAN. In addition, CSAN incurs costs on behalf of the Trust, which are reimbursed.

Funds Distribution	2025	2024
Domain Lodge Operating Expense grant	nil	\$700,000
General grant	nil	nil
Research grant	nil	\$1,481,194

Cancer Society of New Zealand Auckland Northland Division Incorporated

**Separate and Consolidated Statements of
comprehensive revenue and expense
for the year ended 31 March 2025**

		Group	Group	Society	Society
	Note	2025	2024	2025	2024
		\$	\$	\$	\$
Revenue from non-exchange transactions	2	17,951,424	14,663,995	17,951,424	16,845,189
Revenue from exchange transactions	3	2,884,450	2,063,761	2,884,450	2,063,761
Investment income	5	3,524,047	4,524,604	1,859,087	2,379,449
Other income		11,674	18,994	11,674	18,994
Total income		24,371,595	21,271,354	22,706,635	21,307,393
Administration expenses	6	3,715,312	3,722,832	3,598,030	3,596,828
Research costs		2,644,507	2,557,586	2,644,507	2,557,586
Support service expenses		3,869,868	3,805,226	3,869,868	3,805,226
Domain Lodge accommodation expenses		2,340,729	2,255,326	2,340,729	2,255,326
Fundraising & promotion costs		4,617,282	4,133,764	4,617,282	4,133,764
Health promotion costs		483,060	323,725	483,060	323,725
Total expenses		17,670,760	16,798,459	17,553,476	16,672,455
Surplus for the year attributable to members		6,700,835	4,472,895	5,153,159	4,634,938
Net surplus and total comprehensive revenue and expense for the period attributable to members		6,700,835	4,472,895	5,153,159	4,634,938

Cancer Society of New Zealand Auckland Northland Division Incorporated

Separate and Consolidated Statements of changes in net assets/equity for the year ended 31 March 2025

	Note	Accumulated funds Total \$
Society		
2024		
Balance at 1 April 2023		31,181,161
Net surplus and total comprehensive revenue and expense		4,634,938
Balance at 31 March 2024		35,816,099
Society		
2025		
Balance at 1 April 2024		35,816,099
Net surplus and total comprehensive revenue and expense		5,153,159
Balance at 31 March 2025		40,969,258
Group		
2024		
Balance at 1 April 2023		53,317,596
Net surplus and total comprehensive revenue and expense		4,472,895
Balance at 31 March 2024		57,790,491
Group		
2025		
Balance at 1 April 2024		57,790,491
Net surplus and total comprehensive revenue and expense		6,700,835
Balance at 31 March 2025		64,491,326


Cancer Society of New Zealand Auckland Northland Division Incorporated

Separate and Consolidated Statements of financial position
As at 31 March 2025

		Group	Group	Society	Society
	Note	2025	2024	2025	2024
		\$	\$	\$	\$
Equity					
Accumulated funds		64,491,326	57,790,491	40,969,258	35,816,099
Total Equity		64,491,326	57,790,491	40,969,258	35,816,099
Current liabilities					
Trade payables - exchange transactions	12	186,286	587,307	161,038	557,148
Income in advance		1,358,999	152,140	1,358,999	152,140
Employee benefits	13	584,880	524,547	584,880	524,547
Total current liabilities		2,130,165	1,263,994	2,104,917	1,233,835
Total liabilities		2,130,165	1,263,994	2,104,915	1,233,835
Total equity and liabilities		66,621,491	59,054,485	43,074,176	37,049,934
Non-current assets					
Investments	9	45,041,190	42,158,737	21,485,602	20,142,358
Property, plant and equipment	10	7,320,789	3,274,586	7,320,789	3,274,586
Properties held for strategic purposes	11	5,640,568	5,028,403	5,640,568	5,028,403
Total non-current assets		58,002,547	50,461,726	34,446,959	28,445,347
Current assets					
Cash and cash equivalents	7	2,383,567	2,198,970	2,383,567	2,198,970
Investments	9	6,000,000	6,000,000	6,000,000	6,000,000
Receivables - exchange transactions	8	111,522	170,131	119,794	181,959
GST receivable		123,855	223,658	123,855	223,658
Total current assets		8,618,944	8,592,759	8,627,216	8,604,588
Total assets		66,621,491	59,054,485	43,074,175	37,049,934

For and on behalf of the Board

Dated: 13 August 2025



President



Chief Executive

**Separate and Consolidated Statements of cash flows
for the year ended 31 March 2025**

	<i>Note</i>	Group 2025 \$	Group 2024 \$	Society 2025 \$	Society 2024 \$
Cash flows from operating activities					
Cash provided from:					
Receipts from public, services and other sources		22,106,414	16,744,031	22,106,414	19,322,308
Interest received		463,605	339,314	463,605	339,314
Dividends received		14,066	12,824	14,066	12,824
		22,584,085	17,096,169	22,584,085	19,674,446
Cash applied to:					
Payments to suppliers and to employees		(17,156,956)	(16,732,932)	(17,023,206)	(16,616,697)
Net cash from operating activities		5,427,129	363,237	5,560,879	3,057,749
Cash flows from investing activities					
Cash provided from:					
Proceeds from sale of property, plant & equipment		11,674	18,696	11,674	18,696
Proceeds from sale of investments		20,220,699	2,694,512	20,086,949	-
Cash applied to:					
Purchase from investments		(20,086,949)	(2,000,000)	(20,086,949)	(2,000,000)
Purchase of property, plant & equipment		(5,387,956)	(396,385)	(5,387,956)	(396,385)
Net cash from investing activities		(5,242,532)	316,823	(5,376,282)	(2,377,689)
Net increase in cash, and cash equivalents		184,597	680,060	184,597	680,060
Cash and cash equivalents at the beginning of the year		2,198,970	1,518,910	2,198,970	1,518,910
Cash and cash equivalents at the end of the year	7	2,383,567	2,198,970	2,383,567	2,198,970

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated Financial
Statements
For the year ended 31 March 2025

1 Statement of significant accounting policies for the year

Reporting entity

The Cancer Society of New Zealand Auckland Northland Division Incorporated ("the Society") is an incorporated society incorporated in New Zealand under the Incorporated Societies Act 1908 and registered under the Charities Act 2005.

Group

The separate and consolidated group consolidated general purpose financial report (hereafter collectively referred to as "The general-purpose financial report") includes the Society and the Davis Carr Cancer Society Endowment Trust (together referred to as the "Group" and individually as "Group Entities") as described in note 14.

The Society is a public benefit entity for the purposes of financial reporting. The Society is domiciled and operates in New Zealand.

The primary objective of the Society is to improve community well-being by reducing the incidence and impact of Cancer. As such, the Society supports research, fosters and advocates health promotion, and provides support and comfort to people suffering from cancer and their whanau.

Statement of compliance and basis of preparation

The general-purpose financial report comprises the statement of service performance and the financial statements for the Society and the Group, and has been prepared in accordance with the Charities Act 2005 and New Zealand Generally Accepted Accounting Practice ("NZ GAAP"). It complies with Public Benefit Entity International Public Sector Accounting Standards ("PBE IPSAS") and other applicable Financial Reporting Standards, as appropriate for Tier 2 not-for-profit public benefit entities ("Tier 2 PBE Standards"), for which all reduced disclosure regime exemptions have been adopted. The Group and Society are eligible to apply Tier 2 PBE Standards because they both have annual expenditure less than \$33 million and they are not publicly accountable.

These financial statements have been prepared under the historical cost basis except for the following material items in the statement of financial position, which are measured at fair value:

- Financial assets at fair value through surplus or deficit. (note 9).

The financial statements are presented in New Zealand dollars (\$), which is the functional currency of the Society and Group's presentation currency, rounded to the nearest dollar. There has been no change in the functional currency of the Society during the year.

Foreign currency

Transactions in foreign currencies are converted at the New Zealand rate of exchange at the date of transaction. At the reporting date, any foreign currency monetary assets and liabilities are translated at the exchange rate at that date and any resulting exchange variations are included in surplus or deficit.

Foreign currency differences arising on retranslation are recognised in surplus or deficit.

Critical accounting estimates and assumptions

The preparation of the general-purpose financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period which the estimates are revised and in any future periods affected.

From April 2024, the Society changed its accounting estimate for depreciating property, plant and equipment, so as to apply more fully a components approach. Management takes the view that this policy provides more representative and relevant information, because it deals more accurately with the components of property, plant, and equipment. The policy has been applied prospectively from the start of 2024, because it was not practicable to estimate the effects of applying the policy retrospectively. Accordingly, the adopting of the new policy has no effect on prior periods. The effect on the current year is to decrease depreciation expense by \$24,227.

Information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the general-purpose financial report are noted below:

- The Board have judged that the Society and Group's investment properties are held for strategic purpose and therefore the properties are accounted for under PBE IPSAS 17 Property, Plant and Equipment and not PBE IPSAS 16 Investment Property (refer to note 11). The Society has adopted a strategy of purchasing properties adjacent to its Domain Lodge property, as they

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated Financial
Statements
For the year ended 31 March 2025

become available for sale, for the purpose of providing for the future development of Domain Lodge, having regard to its close proximity to the Auckland Public Hospital. As a result of a change in use, 3 of these properties were transferred to operational assets and recorded as part of property, plant and equipment. There was nil impact to the property values as a result of the change in classification.

•The Board have judged that the Davis Carr Cancer Society Endowment Trust (Trust) is a special purpose entity controlled by the Society as the board appoints the trustees and the Society is the beneficiary of the Trust (refer to note 14).

•Revenue from bequests and legacies: Where there is a life interest associated with the bequest or legacy or the bequest or the legacy is being contested, the revenue from the bequest and legacy is not recognised until the revenue is measurable and probable.

•Statement of Service Performance: In compiling the Group's Performance report, the Group made judgements in relation to which outcomes and outputs best reflect the achievement of the Group's primary purposes. One Statement of Service Performance has been presented covering the Society and Group on the basis the primary aims and objectives of both are aligned.

Changes in accounting policies

The accounting policies have been applied consistently to all periods presented in these financial statements

2 Revenue from non-exchange transactions

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Bequest and legacies				
- For general purposes	5,274,565	5,848,233	5,274,565	5,848,233
- For research	452,056	1,303,104	452,056	1,303,104
Donations, appeals, grants & events and memoriam	12,224,803	7,512,658	12,224,803	9,693,851
Total revenue from non-exchange transactions	17,951,424	14,663,995	17,951,424	16,845,189

Non-exchange transactions are those where the Group receives an inflow of resources (i.e. cash and other tangible or intangible items) but provides no (or nominal) direct consideration in return.

The following specific recognition criteria in relation to the Group's non-exchange transaction revenue streams must also be met before revenue is recognised.

Fundraising

The Group's fundraising activities involve public cash collections. Fundraising non-exchange revenue is recognised at the point at which cash is received.

Volunteer service

The Society would be unable to operate without the extensive volunteer service it receives from members, supporters, service groups and the general public. These services relate to both raising revenue and service delivery. Principal volunteer services include street collectors for Daffodil Day, entrants and organisers of Relay for Life events, numerous small fund-raising events sponsored by individuals and service clubs, board members who provide governance to the Group, drivers who transport cancer patients to their treatment and meal service providers who deliver meals to cancer patients homes. Generally, the contributions made by individuals is not recorded in detail. No complete record of hours is available and the diverse nature of contribution and individuals involved means it is not possible to reliably value the services they provide. For this reason the value of volunteer services is not recognised as revenue.

Grants, donations, legacies and bequests

The recognition of non-exchange revenue from grants, donations, legacies, and bequests depends on the nature of any stipulations attached to the inflow of resources received, and whether this creates a liability (i.e. present obligation) rather than the recognition of revenue.

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated Financial
Statements
For the year ended 31 March 2025

2 Revenue from non-exchange transactions (continued)

Stipulations that are 'conditions' specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, resulting in the recognition of a non-exchange liability that is subsequently recognised as non-exchange revenue as and when the 'conditions' are satisfied.

Stipulations that are 'restrictions' do not specifically require the Group to return the inflow of resources received if they are not utilised in the way stipulated, and therefore do not result in the recognition of a non-exchange liability, which results in the immediate recognition of non-exchange revenue.

3 Revenue from exchange transactions

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Services income	270,843	163,458	270,843	163,458
Revenue from property rentals	306,663	248,870	306,663	248,870
Revenue from Domain Lodge accommodation	2,306,944	1,651,433	2,306,944	1,651,433
Total revenue from exchange transactions	2,884,450	2,063,761	2,884,450	2,063,761

Rendering of services

The Group's services includes information and health promotion services provided.

Revenue from services rendered is recognised in surplus or deficit in proportion to the stage-of-completion of the transaction at the reporting date. The stage of completion is assessed by reference to work performed at reporting date for services income.

Amounts received in advance for services to be provided in future periods are recognised as a liability until such time as the service is provided.

Rental income on properties held for strategic purposes

Rental income from properties held for strategic purposes is recognised in surplus or deficit on a straight-line basis over the term of the lease. Lease incentives granted are recognised as an integral part of the total rental income, over the term of the lease.

Revenue from Domain Lodge accommodation

Revenue from Domain Lodge accommodation (rental of rooms) is recognised in surplus or deficit when rooms are occupied.

4 Employee benefit costs

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Salaries and wages	6,471,507	6,090,186	6,471,507	6,090,186
Contributions to medical insurance	126,321	102,231	126,321	102,231
Total employee benefit costs	6,597,828	6,192,417	6,597,828	6,192,417

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated
Financial Statements
For the year ended 31 March 2025

5 Investment income

Recognised in revenue	Group 2025 \$	Group 2024 \$	Society 2025 \$	Society 2024 \$
<i>Dividend income on financial assets at fair value through surplus or deficit</i>				
Dividends	14,066	12,824	14,066	12,824
<i>Interest income from financial assets at amortised cost</i>				
Interest on term deposits and bank balance	463,605	327,656	463,605	327,656
<i>Interest/distribution income on financial assets at fair value through surplus or deficit</i>				
Interest / distribution income on bonds and managed funds	400,489	585,259	-	-
<i>Revaluation of investments at fair value through surplus or deficit</i>				
Stock, bonds and managed funds	2,645,887	3,598,865	1,381,416	2,038,969
Total financial income	3,524,047	4,524,604	1,859,087	2,379,449

Investment income comprises interest income on financial assets, gains on financial assets at fair value through surplus or deficit and dividend income. Interest income is recognised as it accrues in surplus or deficit, using the effective interest method. Income from dividends is recognised when the Group's right to receive payment is established, and the amount can be reliably measured.

6 Administration expenses

	Group 2025 \$	Group 2024 \$	Society 2025 \$	Society 2024 \$
<i>Administration expenses include the following:</i>				
Audit fee (for the audit of the financial statements) – BDO Auckland	70,935	53,080	52,714	42,862
Depreciation on property, plant & equipment (note 10)	659,063	580,757	659,063	580,757
Depreciation on properties held for strategic purposes (11)	69,925	69,925	69,925	69,925
Cancer Society Levy	786,465	873,851	786,465	873,851
Insurance	177,864	156,896	177,864	156,896
Personnel Costs	904,136	901,625	904,136	901,625
IT costs	459,290	298,616	459,290	298,616
Property Costs	310,148	497,152	310,148	497,152
Other administration expenses	277,486	290,930	178,425	175,144
Total administration expenses	3,715,312	3,722,832	3,598,030	3,596,828

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated Financial
Statements

For the year ended 31 March 2025

7 Cash and cash equivalents

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Cash at bank on call	2,383,567	2,198,970	2,383,567	2,198,970
Total cash and cash equivalents	2,383,567	2,198,970	2,383,567	2,198,970

8 Receivables - exchange transactions

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Accounts receivable	110,205	166,997	118,477	178,825
Other receivable	1,317	3,134	1,317	3,134
Total receivables - exchange transactions	111,522	170,131	119,794	181,959

As at 31 March 2025 and 2024 there were no impairment allowances.

9 Investments

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
<i>Current investments</i>				
Financial assets at amortised cost				
- term deposits with maturity under 12 months	6,000,000	6,000,000	6,000,000	6,000,000
	6,000,000	6,000,000	6,000,000	6,000,000
<i>Term investments</i>				
Financial assets at fair value through surplus or deficit				
- shares	858,450	745,152	858,450	745,152
Financial assets at fair value through surplus or deficit				
- managed funds	44,182,740	41,413,585	20,627,152	19,397,206
	45,041,190	42,158,737	21,485,602	20,142,358

Financial assets at amortised cost - term deposits

The term deposits held by the Society are managed by ANZ Bank New Zealand Limited. The average interest rate of the term deposits held on 31 March 2025 is 5.30 percent (2024 is:4.65 percent).

Financial assets at fair value through surplus or deficit - shares

The shares held by the Society are listed on the New Zealand and London stock exchanges.

Financial assets at fair value through surplus or deficit - investments in managed funds Group

The investments are held by the Society in accordance with the Investment Policy Statement and are approved by the Board. The Board is advised by Mapua Wealth Ltd and previously ANZ Investments (until August 2024). The investments held by the Trust are managed by Nikko Asset Management New Zealand Limited, and Simplicity Limited, and are approved by the Board in accordance with the relevant Statement of Investment Policies and Objectives and as advised by Mapua Wealth Limited.

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the separate and consolidated Financial
Statements

For the year ended 31 March 2025

The Group holds investments which have been classified at fair value through surplus or deficit. Fair value for the various investments is based on the methodologies outlined in PBE IPSAS 41 Financial Instruments and is determined as follows:

Cash funds - at face value of the amounts deposited or drawn

Unit trusts - by reference to the quoted price in active markets for identical assets or liabilities or quoted prices for identical or similar instruments in inactive markets

Listed government and local government securities - by reference to quoted bid price

Unlisted investments - at valuation based on arm's length transactions, reference to other instruments that have substantially the same characteristics, discounted cash flow analysis and other pricing models

The Group's investments in managed funds include cash balances. These cash balances are recorded as part of the overall investment fund because although they would otherwise meet the definition of cash and cash equivalents, they form an integral part of the investment fund which includes an allocation across various types of investments to balance the policies and objectives of the Trust with regard to its investment fund.

10 Property, plant and equipment

	Land	Buildings	Plant & Equipment	Motor Vehicles	WIP	Total
	\$	\$	\$	\$	\$	\$
Cost						
Bal at 1/4/24	300,944	12,241,748	935,214	497,046	-	13,974,952
Acquisitions	843,454	-	770,619	113,000	1,003,737	2,730,810
Transferred from Strategic Properties	1,651,207	844,426	-	-	-	2,495,633
Disposals	-	-	(244,731)	(48,495)	-	(293,226)
Bal at 31/3/25	2,795,605	13,086,174	1,461,102	561,551	1,003,737	18,908,169
Accumulated Depreciation						
Bal at 1/4/24	-	9,949,594	531,281	219,490	-	10,700,366
Dep for year	-	408,058	176,455	74,550	-	659,063
Transferred from Strategic Properties	-	521,177	-	-	-	521,177
Release on Disposal	-	-	(244,731)	(48,495)	-	(293,226)
Bal at 31/3/25		10,878,829	463,006	245,545	-	11,587,380
Carrying Amounts 31 March 2024	300,944	2,292,154	403,932	277,556	-	3,274,586
Carrying Amounts 31 March 2025	2,795,605	2,207,345	998,096	316,006	1,003,737	7,320,789

Items of property plant and equipment are initially measured at cost, except those acquired through non-exchange transactions which are instead measured at fair value as their deemed cost at initial recognition.

Property, plant and equipment are shown at cost, less accumulated depreciation and impairment losses. All of the Group's items of property plant and equipment are subsequently measured in accordance with the cost model.

Subsequent costs

Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group. Ongoing repairs and maintenance is expensed as incurred.

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the Financial Statements
for the year ended 31 March 2025

Depreciation

Depreciation is provided on a straight-line basis on all property, plant and equipment at rates that will write off the cost of the assets to their estimated residual values over their useful lives. Depreciation is charged to surplus or deficit. Land is not depreciated. The useful lives and associated depreciation rates of major classes of assets have been estimated for current and prior period as follows:

Asset	Economic Life
Plant, Computers, and Equipment	3 – 8 years
Motor Vehicles	6.7 years
Buildings	30 years

In April 2024 the useful life of plant and equipment was split into 3, 5 and 8 year groups (2024 -3 and 5 years). Management takes the view that this policy provides more representative and relevant information, because it deals more accurately with the components of property, plant, and equipment.

Depreciation methods, useful lives, and residual values are reviewed at reporting date and adjusted if appropriate. On 31 March 2025, three properties were reclassified from properties held for strategic purposes. There was nil variance to values as a result of the reclassification

11 Properties held for strategic purposes

Group and Society	Land	Buildings	Total
Cost	\$	\$	\$
Bal at 1/4/24	4,175,651	2,097,760	6,273,411
Transferred to Society PPE	(1,651,207)	(844,426)	(2,495,633)
Acquisitions	2,656,546		2,656,546
Bal at 31/3/25	5,180,990	1,253,334	6,434,324
Accumulated Depreciation			
Bal at 1/4/24	-	1,245,008	1,245,008
Dep for year	-	69,925	69,925
Transferred to Society PPE	-	(521,177)	(521,177)
Bal at 31/3/25	-	793,756	793,756
Carrying Amounts			
At 31 March 2024	4,175,651	852,752	5,028,403
At 31 March 2025	5,180,990	459,578	5,640,568

Properties held for strategic purposes comprise a number of domestic properties that are used for accommodation purposes. On 31 March 2025 the Board recognised that 3 buildings were now primarily used as patient accommodation, and the assets were transferred to property plant and equipment (note 10)

Properties which are held to meet service delivery objectives are accounted for under PBE IPSAS 17 Property, Plant and Equipment. Refer to "property, plant and equipment" above.

Asset	Economic Life	
Buildings	30 years	Straight Line Method

The residual value, depreciation method and useful life of buildings is reviewed, and adjusted if applicable, at each financial year-end.

12 Trade payables - exchange transactions

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
Trade payables from exchange transactions	186,287	587,307	161,039	557,148
Total trade payables - exchange transactions	186,287	587,307	161,039	557,148

13 Employee benefit liabilities

	Group 2025	Group 2024	Society 2025	Society 2024
	\$	\$	\$	\$
<i>Current</i>				
Holiday pay accrual (short term employee benefit)	314,326	304,070	314,326	304,070
Accrued expense (short term employee benefit)	270,554	220,477	270,554	220,477
Total current employee benefit liabilities	584,880	524,547	584,880	524,547

Short-term employee benefits

Employee benefits that the Group expects to be settled wholly within 12 months of reporting date are measured at nominal values based on accrued entitlements at current rates of pay on an undiscounted basis.

These include salaries and wages accrued up to reporting date, annual leave earned to, but not yet taken at reporting date, expected to be settled within 12 months.

14 Group entity

The Society established the Davis Carr Cancer Society Endowment Trust (the Trust) on 31 March 2008 to maintain and develop Domain Lodge, assist with the work and activities of the Society and provide funds for cancer research and treatment and assistance to those with cancer. The Society has the power to govern the financial and operating policies of the Trust so as to benefit from the Trust's activities. The Board have judged that the Trust is a Group entity controlled by the Society as the Board appoints the trustees and the Society is the beneficiary of the Trust.

The reporting date for the Trust is 31 March. The principal activity of the Trust is investment.

Basis of consolidation

Controlled entities

Controlled entities are entities controlled by the Group, being where the Group has power to govern the financial and operating policies of another entity so as to benefit from that entity's activities. The financial statements of the Group's controlled entities are included in the financial statements from the date that control commences until the date that control ceases.

Subsequent changes in a controlled entity that do not result in a loss of control are accounted for as transactions with controllers of the controlling entity in their capacity as controllers, within net assets/equity.

Transactions eliminated on consolidation

Intra-group balances, and any unrealised income and expenses arising from intra-group transactions are eliminated in preparing the consolidated financial statements.

15 Related party transactions

The following transactions were carried out with related parties during the year.

- Cancer Society of New Zealand Incorporated is partly funded by the Society. The Society is entitled to representation on the board of the Cancer Society of New Zealand Incorporated. In 2025 the Society paid administration and research levies of \$1,309,467 which is equal to 38% of the total divisional levy (2024 - \$1,028,390). It also received \$88,183 for reimbursement of expenses incurred on behalf of them (2024 - \$2,690)
- In 2025, the Society received \$nil grants from the Davis Carr Cancer Society Endowment Trust (the "Trust"). (2024: Received \$2,181,193) The balance as at 31 March 2025 owing to the Society is \$8,272. (2024 - \$11,828).

Cancer Society of New Zealand Auckland Northland Division Incorporated
Notes to and forming part of the Financial Statements
for the year ended 31 March 2025

- c. In the current year, the Waikato/ Bay of Plenty Division Cancer Society of New Zealand (Incorporated) paid the Society \$146,864 (2024: \$258,727) for fundraising expertise and services.
- d. In 2025, the Society paid \$115,063 to Cancer Society Wellington Division for call centre services (2024: \$57,750).
- There are no fees paid to any board member.

Key management personnel

The Directors of the Society, Trustees of the Trust and executive team of the Society are considered to be the key management personnel of the Group and Society. Directors of the Society and Trustees of the Trust receive no remuneration.

Group and Society	2025	Number of	2024	Number of
	\$	individuals	\$	individuals
Compensation to key management personnel:				
Short term employee benefits	<u>1,275,109</u>	8	<u>1,144,149</u>	9
	<u>1,275,109</u>		<u>1,144,149</u>	

16 Financial instruments

Fair values

All financial instruments are recognised in the statement of financial position and are stated at carrying amounts that are also a reasonable approximation of their fair values.

Classification of financial instruments

	Group	Group	Society	Society
	2025	2024	2025	2024
	\$	\$	\$	\$
Current financial assets				
<i>Financial assets at amortised cost</i>				
Cash and cash equivalents	2,383,567	2,198,170	2,383,567	2,198,170
Term deposits with maturity under 12 months	6,000,000	6,000,000	6,000,000	6,000,000
Accounts receivable	110,205	166,998	118,477	178,826
Other receivables	1,317	3,134	1,317	3,134
Non current financial assets				
<i>Financial assets at fair value through surplus or deficit</i>				
-shares	858,450	745,152	858,450	745,152
-managed funds	44,182,740	41,413,585	20,627,152	19,397,206
Current financial liabilities				
<i>Financial liabilities measured at amortised cost</i>				
Trade payables	186,287	587,307	161,039	557,148

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument.

The Group derecognises a financial instrument when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability.

The Group derecognises a financial liability when its contractual obligations are discharged, cancelled, or expire.

Financial instruments are initially measured at fair value, plus for those financial instruments not subsequently measured at fair value through surplus or deficit, directly attributable transaction costs. Subsequent measurement is dependent on the classification of the financial instrument, and is specifically detailed in the accounting policies below.

16 Financial instruments (continued)

Financial assets

The Society and Group's financial assets are classified as either financial assets at amortised cost, or financial assets at fair value through surplus or deficit.

The classification of the financial assets are determined at initial recognition .

The categorisation determines subsequent measurement and where any resulting income and expense is recognised.

The categorisation is on the basis of both:

- (a) The entity's management model for financial assets; and
- (b) The contractual cash flow characteristics of the financial asset.

Financial assets at amortised cost

A financial asset is measured at amortised cost if the financial asset is held within a management model whose objective is to hold financial assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

After initial recognition, these are measured at amortised cost using the effective interest rate method, less any allowance for impairment.

The Group's cash and cash equivalents, term deposits, and receivables fall into this category of financial instruments.

Cash and cash equivalents represent highly liquid investments that are readily convertible into a known amount of cash with an insignificant risk of changes in value, with original maturities of three months or less.

Term deposits are those cash balances with original maturities of more than three months. Where a term deposit matures within 12 months, it is classified as a current asset. All other term deposits are classified as non-current assets.

Financial assets at fair value through surplus or deficit

Financial assets classified at fair value through surplus or deficit are subsequently measured at fair value with gains or losses being recognised in surplus or deficit.

Financial assets at fair value through surplus or deficit include equity and debt securities, and managed fund investments. These investments are classified as financial assets at fair value through surplus or deficit because they are managed and their performance is evaluated on a fair value basis and they do not meet the criteria for any other category of financial instruments.

Financial Liabilities

Financial liabilities include payables (from exchange and non-exchange transactions).

The Group's financial liabilities are subsequently measured at amortised cost using the effective interest rate method.

Impairment of non-derivative financial assets

Financial assets as amortised cost are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset. Impairment is recognised in surplus or deficit.

Financial commitments:

The group has resolved to provide support to the following entities in the next financial year:

	Next 12 months	Between 1 - 5 years	Beyond 5 years
	\$	\$	\$
Group and Society 2025			
Cancer Trials NZ - clinical trials	120,000		
ACS Research Centre funding and other fundraising costs	1,516,000		
Te Aka, UoA Centre for Cancer Research	625,000		
	<u>2,261,000</u>	<u>-</u>	<u>-</u>
	Next 12 months	Between 1 - 5 years	Beyond 5 years
	\$	\$	\$
Group and Society 2024			
Cancer Trials NZ - clinical trials	170,000	120,000	
ACS Research Centre funding and other fundraising costs	1,588,000	1,000,000	
Te Aka, UoA Centre for Cancer Research	375,000	625,000	
	<u>2,133,000</u>	<u>1,745,000</u>	<u>-</u>

17 Contingencies

Contingent liability

The Group and Society have no contingent liabilities as at 31 March 2025 (2024 - \$ nil).

Contingent assets

At reporting date the Group and Society has received intimation concerning bequests which will be received in the future. These bequests cannot be quantified by the Group and Society as at reporting date due to fact that they cannot be reliably measured. A register is maintained of all the future bequests receivable.

This is available from the Domain Lodge, 1 Boyle Crescent, Grafton.

18 Events after the reporting date

On 11 July 2025 the Society signed a contract appointing Klein Limited architects to design an accommodation facility on land held at Hospital Road Whangarei. Earthworks and construction is expected to commence in the 2025-2026 year.

19 Financial commitments and operating leases

Leases as lessee

At balance date the Group and Society had operating lease commitments of \$nil (2024 - \$nil).